002382 蓝帆医疗
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入1,454,84932.96%4,927,0754,900,4788,108,5867,869,425
减:营业总成本1,565,05524.74%5,560,7625,524,1165,727,8724,088,485
    其中:营业成本1,241,54230.13%4,320,9974,398,9734,301,5512,801,370
               财务费用62,2455.43%124,25833,873167,490280,111
               资产减值损失(13,676)-56.72%(72,256)(82,338)(2,117,249)(1,769,164)
公允价值变动收益(11)-100.02%70,628(6,742)1,098,4721,057
投资收益(4,317)-163.22%14,408257,71224,30936,100
    其中:对联营企业和合营企业的投资收益(4,546)-203.02%4,438(24,104)2,52732,001
营业利润(120,402)23.20%(604,846)(402,079)1,390,5482,038,479
利润总额(103,574)13.82%(622,610)(405,860)1,347,3582,018,388
减:所得税费用(4,835)-64.70%(54,250)(33,544)191,649255,344
净利润(98,739)27.74%(568,360)(372,316)1,155,7091,763,044
减:非控股权益181-----0(1)4,567
股东净利润(98,920)27.97%(568,360)(372,316)1,155,7091,758,477

市场价值指针
每股收益 (元) *-0.10025.00%-0.560-0.3701.1301.820
每股派息 (元) *------0.400--0.400
每股净资产 (元) *8.922-12.17%9.29410.290--9.579
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见--
回页顶
备注: *未调整数据
#只提供简体内容